STRIDE-CAP
STRIDE-CAP Pilot and Study
The STRIDE-CAP pilot study will precede the full STRIDE-CAP study and aims to establish the feasibility and methodological framework for the subsequent international, observational test-negative design (TND) case-control study.
The full study will evaluate the vaccine effectiveness of an adult-specific pneumococcal conjugate vaccine within a real-world context.
Operations and Site Selection
Ecraid will assume responsibility for the study's operational management in Europe and the strategic selection of European study sites. The CLIN-Net team, a component of Ecraid, has successfully identified and selected 21 sites across four European nations: Spain, Italy, Germany, and the Netherlands.
The projected participant recruitment period, spanning from April to September 2025, necessitates a rapid study execution, which Ecraid's warm-base network is ideally positioned to provide.
Sponsor and CRO
Merck Sharp & Dohme LLC will serve as the financial sponsor and study sponsor within the European Union.
IQVIA will function as the global Contract Research Organization (CRO) overseeing the study's implementation.